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cTATE-OF-THE-ART PAPER1637Cardiac Fatty Acid Load in Heart Failureionel H. Opie, Juhani Knuuti
pie and Knuuti describe how the hyperadrenergic state caused by heart failure (HF)
ncreases circulating plasma free fatty acids (FFAs), which leads to impaired glucose
etabolism and insulin resistance. In the heart, FFAs can induce mitochondrial uncoupling
eading to the generation of reactive oxygen species (ROS), inflammatory proteins, and
nsulin resistance. They propose that these derangements be addressed by metabolic therapy,
hich has 3 aims: 1) to decrease hyperadrenergic drive; 2) to inhibit lipotoxicity and
lucotoxicity; and 3) to increase glucose uptake by muscle. These aims are respectively
chieved by: 1) beta-adrenergic blockade and other measures that reduce the mechanical load
n the heart; 2) drugs that inhibit fatty acid oxidation (trimetazidine, perhexiline); and 3)
ncreasing the transport of glucose into the cells by exercise training and metformin. The data
ehind these recommendations is reviewed and is found to be sparse for hard clinical
utcomes, but it does provide reasons for hope and further study.TATE-OF-THE-ART PAPER1647Outpatient Management of Ventricular Assist Devicesean R. Wilson, Michael M. Givertz, Garrick C. Stewart, Gilbert H. Mudge, Jr
ver the last few decades, much progress has been made in the development and refinement
f ventricular assist devices (VADs), medical devices capable of maintaining circulatory output
f the diseased ventricle. Initially designed as a temporary support to allow ventricular
ecovery or bridge patients to cardiac transplant, these devices are now being used as a
ermanent form of “destination” therapy; this means that patients with VADs are returning
o their communities. In this paper, Wilson and colleagues discuss: 1) the spectrum of VADs
or outpatient therapy, including their basic physiology and hemodynamics; 2) the
ultidisciplinary approach required to care for a patient with such a device; 3) routine general
ardiac issues that are encountered; 4) associated long-term device and nondevice-related
omplications; and 5) the reported overall improvements in quality of life.(continued on page A-22)
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HIEWPOINT1660Micronutrient Supplementation May Improve HF OutcomesMacronutrients
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Micronutrients ictor Soukoulis, Jamil B. Dihu, Michael Sole, Stefan D. Anker, John Cleland, Gregg C. Fonarow,
arco Metra, Evasio Pasini, Theresa Strzelczyk, Heinrich Taegtmeyer, Mihai Gheorghiade
oukoulis and colleagues propose that one of the reasons that morbidity and mortality remain
igh for patients with heart failure (HF) is that current pharmacological regimens do not fully
ddress some unique requirements of the heart for energy metabolism. The heart requires a
ontinuous supply of energy-providing substrates and amino acids, and HF appears to cause
efects in cardiac substrate metabolism and utilization. These alterations may be related to
eficiencies in key micronutrients, which theoretically could be reversed by micronutrient
upplementation. This review explores the evidence that supplementation of coenzyme Q10,
-carnitine, thiamine, and taurine improves outcomes, and it concludes that there is
ustification for a prospective trial to examine the effects of micronutrient supplementation on
orbidity and mortality in patients with HF.LINICAL RESEARCH
1674plerenone May Reduce Cardiac Collagen
Turnover and Reduce the Increase in Cardiac Stiffnesseorge J. Mak, Mark T. Ledwidge, Chris J. Watson, Dermot M. Phelan, Ian R. Dawkins,
iamh F. Murphy, Anil K. Patle, John A. Baugh, Kenneth M. McDonald
erum levels of markers of collagen turnover correlate with myocardial fibrosis and clinical
utcomes. It is currently unknown if collagen metabolism can be beneficially modulated to
esult in improvements in diastolic function and clinical status in subjects with heart failure
nd preserved ejection fraction (HFPEF). Mak and colleagues randomized 44 patients with
FPEF to control or eplerenone at escalating doses. Serum markers of collagen turnover and
nflammation were analyzed at baseline and at 6 and 12 months. Doppler echocardiographic
ssessment of diastolic filling indexes were also obtained. In control patients, there were
teady increases in these markers over time, but eplerenone attenuated the increase at 12
onths and was associated with modest improvements in diastolic function. This study
emonstrates progressive increases in markers of collagen turnover and inflammation in
FPEF, and these markers may serve as surrogates for worsening diastolic dysfunction.(continued on page A-23)
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ELINICAL RESEARCH1683Meta-Analysis of Remote Monitoring for HF Patients Confirms Benefitsatherine Klersy, Annalisa De Silvestri, Gabriella Gabutti, François Regoli, Angelo Auricchio
lersy and colleagues performed a meta-analysis of studies that compared remote patient
onitoring (RPM) versus standard care for patients with chronic heart failure (HF). RPM
ould occur via regularly scheduled structured telephone contacts between patients and health
are providers or via electronic transfer of physiological data using external, wearable, or
mplantable electronic devices. There were 20 articles reporting outcomes of randomized
ontrolled trials (RCTs) and 12 papers describing cohort studies totaling almost 9,000
atients. Both RCTs and cohort studies showed that RPM was associated with a significantly
ower mortality (RCTs relative risk [RR]: 0.83, cohort RR: 0.53) and hospitalizations (RCTs
R: 0.93, cohort RR: 0.52). This analysis demonstrates that RPM confers a significant
rotective clinical effect in patients with chronic HF compared with usual care.LINICAL RESEARCH
1695ospitalization Frequent in Patients With a History of HF,
But Is Often for Non-HF Conditionshannon M. Dunlay, Margaret M. Redfield, Susan A. Weston, Terry M. Therneau, Kirsten Hall Long,
ilay D. Shah, Véronique L. Roger
unlay and colleagues sought to determine the lifetime burden and risk factors for
ospitalization after a diagnosis of heart failure (HF) using a random sample of incident HF
ases in Olmsted County, Minnesota, over nearly 20 years. Among 1,077 HF patients, 4,359
ospitalizations occurred. Over 80% of patients were hospitalized at least once, and 43% were
ospitalized 4 times. However, the primary reason for hospitalization was HF in only 17%
f hospitalizations and other cardiovascular conditions in an additional 22%. Sixty-two
ercent of subsequent hospitalizations were for noncardiovascular reasons. Multiple
ospitalizations are common after HF diagnosis, although less than one-half are due to
ardiovascular causes.
ditorial Comment: Soko Setoguchi, Lynne Warner Stevenson, p. 1703(continued on page A-24)
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pLINICAL RESEARCH1706Hypoxia, Not the Frequency of Sleep Apnea, Raises BNPoshua D. Gottlieb, Alan R. Schwartz, Joanne Marshall, Pamela Ouyang, Linda Kern, Veena Shetty,
aria Trois, Naresh M. Punjabi, Cynthia Brown, Samer S. Najjar, Stephen S. Gottlieb
leep apnea is strongly associated with heart failure (HF), and could conceivably worsen HF
hrough increased sympathetic activity, hemodynamic stress, hypoxemia, and oxidative stress.
ottlieb and colleagues hypothesized that if apneic activity causes acute cardiac stress, it
hould increase B-type natriuretic peptide (BNP). This hypothesis was tested by serially
easuring BNP at 20-min intervals while subjects with HF were being monitored for
vidence of sleep apnea. There was no relationship between BNP and the number of apneic/
ypopneic episodes or the number of arousals. However, the burden of hypoxemia, the time
pent with oxygen saturation below 90%, predicted BNP concentrations. Hypoxemia appears
o be an important factor that underlies the impact of sleep abnormalities on hemodynamic
tress in patients with HF.ditorial Comment: Lee R. Goldberg, p. 1713LINICAL RESEARCH1715Mildly Elevated Cardiac Troponin T Predicts Poor Outcomes in Patients With HFayne L. Miller, Karen A. Hartman, Mary F. Burritt, Diane E. Grill, Allan S. Jaffe
iller and colleagues measured cardiac troponin T (cTnT) every 3 months in stable
utpatients with a history of New York Heart Association functional class III to IV heart
ailure (HF). The primary end point was long-term clinical outcome, specifically death or
ardiac transplantation after at least 1 year of stability. Of the 172 patients, 13% experienced
eath or transplantation during the first year. The remaining patients were divided into 3
roups: 1) those who never had a cTnT elevation (defined as 0.01 ng/ml); 2) those with 1
r more but not all cTnT values elevated; and 3) those who had persistently elevated cTnT
alues. The event rate was 11% in subjects with persistently normal cTnT levels, 19% in
hose with intermittent elevations, and 33% in those with persistently elevated cTnT levels.
hese findings show that elevations in cTnT, even using a low threshold of 0.01 ng/ml,
etected during routine clinical follow-up of ambulatory patients are highly predictive of
oor outcomes.(continued on page A-26)
OCTOBER 27, 2009 (continued) A-26I
EINTERVENTIONAL CARDIOLOGYE
T
e
M
S
m
D
p
s
a
p
a
R
C
H
M
J
R
o
a
i
C
h
C
P
U
J
K
i
m
a
(
(
b
c
e
pNTERVENTIONAL CARDIOLOGY
1722arly Results Show Promise for Transcatheter Implantation
of Pulmonary Valve in Patients With RVOT Conduitsvan M. Zahn, William E. Hellenbrand, James E. Lock, Doff B. McElhinney
his study was designed to evaluate the safety, procedural success, and short-term
ffectiveness of the Melody transcatheter pulmonary valve (Medtronic, Inc., Minneapolis,
innesota) in patients with dysfunctional right ventricular outflow tract (RVOT) conduits.
tandardized entry criteria, implantation, and follow-up protocols were utilized in this
ulticenter study, which also used core laboratories to evaluate results. The initial conduit
oppler mean gradient was 29 mm Hg, and 94% of patients had moderate or severe
ulmonary regurgitation (PR). Implantation was successful in 29 of 30 attempts. There were
ignificant procedural complications in 3 patients. The peak systolic conduit gradient fell
cutely from 37 to 17 mm Hg, and no patient had more than mild PR at the end of the
rocedure. There were no deaths. At 6-month follow-up, conduit Doppler mean gradient
nd PR fraction remained significantly improved. Implantation of the Melody valve for
VOT conduit dysfunction has encouraging acute and short-term outcomes.CARDIOVASCULAR RISK ARDIOVASCULAR RISK
1730igh Central PP Is Independently
Associated With Adverse Cardiovascular Outcomeary J. Roman, Richard B. Devereux, Jorge R. Kizer, Peter M. Okin, Elisa T. Lee, Wenyu Wang,
ason G. Umans, Darren Calhoun, Barbara V. Howard
oman and colleagues have previously shown that central pulse pressure (PP) is a better predictor
f incident cardiovascular disease (CVD) than brachial PP. In this study, they sought to determine
threshold value that predicts adverse outcomes. Radial applanation tonometry was performed
n over 2,000 subjects to determine central blood pressure. Quartiles of central PP predicted a
VD event more strongly than quartiles of brachial PP. Central PP 50 mm Hg predicted
igher risk regardless of sex, age, or diabetes status. Central PP 50 mm Hg predicts adverse
VD outcomes and may serve as a target in intervention strategies.PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH
1735ltrasound-Mediated Destruction of Carrier Microbubbles
for Endovascular Gene Deliveryeremy Kobulnik, Michael A. Kuliszewski, Duncan J. Stewart, Jonathan R. Lindner, Howard Leong-Poi
obulnik and colleagues hypothesized that ultrasound-mediated (UM) destruction of
ntravenously administered deoxyribonucleic acid-bearing carrier microbubbles during their
icrocirculatory transit may be a more effective way of transfecting cells to stimulate
ngiogenesis. In a rat model of hind limb ischemia, UM was compared with intramuscular
IM) injections for the efficiency of transfection with vascular endothelial growth factor
VEGF). Microvascular blood volume and microvascular blood flow (MBF) were measured
y contrast-enhanced ultrasound. The increase in MBF was greater in UM-treated animals
ompared with IM. Immunohistochemistry showed that the VEGF localized to the vascular
ndothelium after UM delivery. These results demonstrate that UM gene delivery produces a
attern of gene expression that may be more efficacious compared with direct IM injections.
